保险覆盖延迟和拒绝对遗传性血管炎患者的后果
Nonie S Arora1, Belinda Nelson2, Laurie Carpenter2
1Department of Internal Medicine, University of Michigan, Ann Arbor, Mich.
The journal of allergy and clinical immunology. In practice
|August 9, 2023
概括
保险延迟和拒绝显著恶化了遗传性血管 (HAE) 患者的健康结果,导致更多的发作,错过工作和增加焦虑. 这些挑战会对患者的福祉和家庭生活产生负面影响.
科学领域:
- 医学遗传学 医学遗传学
- 医疗保健服务研究 医疗服务研究
- 患者倡导 患者倡导
背景情况:
- 遗传性血管 (HAE) 是一种罕见的,可能致命的遗传性疾病,其特点是经常出现血管发作.
- 虽然先进疗法提高了生活质量,但与保险相关的问题,如延迟和拒绝,越来越普遍.
研究的目的:
- 调查保险延迟和拒绝对HAE患者的健康和福祉的影响.
- 了解保险挑战如何影响医疗保健的获取,日常生活和心理状态.
主要方法:
- 一种混合方法的方法,包括在线调查和重点小组,包括20名HAE患者,他们遇到保险问题.
- 专题和分析被用来编码焦点组的成绩单,识别关键的患者经验.
主要成果:
- 70%的HAE患者报告说,由于保险延迟/拒绝,发作频率增加.
- 超过50%的人错过了工作/上学的日子,90%的人经历了更高的焦虑,25%的人有更多的紧急护理/ED访问.
- 患者将药物获取丧失,政策变更通知不足和检索努力列为主要压力因素.
结论:
- 保险延迟和拒绝显著加剧了HAE患者的体验.
- 关键影响包括增加紧急访问,错过工作/学校,增加焦虑,以及对家庭生活的负面影响.
- 解决保险障碍对于改善HAE患者的整体福祉至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Peripheral Artery Disease V: Postoperative Nursing Management
12
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
12
Allergic Reactions
27.8K
Overview
27.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201
Antihypertensive Drugs: Direct Renin Inhibitors
682
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
682
Peripheral Artery Disease I: Introduction
9
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
9


